Home Contents Ask GENTAUR Meet Us Distributors

Mouse monoclonal anti PAI1 Antibody 385 Euro / 1 ml	Active(1) vs latent	mechanism(3)(4)	Epitope(6)	Species cross-reactivity(7)	Data animal models
MA-8H9D4	~3	S	thIs5A	Hu, Cae, (po?)	-
MA-33H1F7	~2	S	hF	hu, Cae, rat, mu, (rab)	(a), (b), (e)
MA-55F4C12	~3	S	hF	Hu, Cae, rat, mu	-
MA-33B8	~3	L(5)	K88/D89/K176/H229	Hu, Cae, rab, po	(d)
MA-35A5	~0.7	NR	Similar to MA-33B8	Hu, Cae, po, (rab?)	-
MA-56A7C10	~25	NR	ts3BhG and RCL	Hu, Cae, po	-
MA-124K1	ND(2)	NR(8)	E212/E220	Rat, mu	(c)

 

⁽¹⁾       All affinity constants or in the order of 5.10⁸ M^-1 to 7.10⁹ M^-1

Some of he indicated ratios are based on a limited number of experiments and are therefore only indicative.

⁽²⁾       ND: Not determined.

⁽³⁾       See also Debrock S et al. Biochim Biophys Acta 1337, 257-266, 1997.

⁽⁴⁾       S: induction of substrate form

L: accelerated conversion to the latent form

NR: Generation of a non-reactive form (not further investigated whether this non-reactive form is the latent form or is reactive-site blocked by the antibody)

⁽⁵⁾       See also Verhamme I et al. J Biol Chem 274, 17511-17517, 1999.

⁽⁶⁾       ‘thIs5A’: residues R300,Q303 and D305; + contribution from hC and hI; see also Naessens D et al. J.Thromb.Haemostas. 1, 1028-1033, 2003

‘hF’: residues E128-R131 and K154; see also Bijnens AP et al. J.Biol. Chem 275, 6375-6380, 2000

‘ts3BhG and RCL’; see also Bijnens et al. J Biol Chem 276, 44912-44918, 2001

‘E212/E220’; see also Ngo TH et al. J Biol Chem 276, 26243-26248, 2001

 ‘K88/D89/K176/H229’; see also Naessens et al. Thromb Haemost 90, 52-58,  2003.

⁽⁷⁾       Cross-reactivity evaluated on ELISA using coated recombinant antigen (human (hu), monkey C. aethiops (Cae), rat (rat), murine (mu), rabbit (rab), porcine (po)).

In some cases it has been observed that a negative outcome in this assay does not a priori exclude binding in the soluble phase (as evidenced in an assay evaluating the inhibition of PAI-1 activity in solution)

⁽⁸⁾       Concomitant to neutralization of PAI-1 activity, this antibody induces an increased vitronectin binding of PAI-1, also resulting in a decreased cell migration. See also Ngo TH et al. J Biol Chem 276, 26243-26248, 2001

                       

(a)     Berry CN et al. Br J Pharmacology 125, 29-34, 1998.

(b)     Rupin A et al. Abstract 1021 at ISTH congress in Washington DC (August 1999), Thromb Haemostas 82 (1999). Rupin A et al Thromb Haemost 86,1528-1531,2001

(c)     Ngo TH et al. Fibrinolysis & Proteolysis 12, 335-339, 1998.

(d)     Montes R et al. Thromb Haemost 84, 65-70, 2000.

(e)     Schoots IG et al. Thromb Haemost 91, 497-505, 2004.

 

Remark:

Isotype of MA-8H9D4        IgG1(kappa)

Isotype of MA-33H1F7       IgG1(kappa)

Isotype of MA-55F4C12     IgG1(kappa)

Isotype of MA-33B8           IgG1(kappa)

Isotype of MA-35A5           IgG1(kappa)

Isotype of MA-56A7C10    IgG1(kappa)

Isotype of MA-124K1          IgG1(kappa)

Isotype of MA-31C9            IgG1(kappa)         Control non-inhibitory antibody, reacts only with human PAI-1, not with murine,rat nor rabbit, very low (if any) with porcine

Isotype of MA-32K3            IgG1(kappa)         Control non-inhibitory antibody, reacts only with rat PAI-1, not with human, porcine, murine nor rabbit

Isotype of MA-14D5           IgG1(kappa)         Antibody detecting a neo-epitope in complexed PAI-1        

 

 

All against PAI-1